UK MHRA · February 11, 2026

IXCHIQ Chikungunya vaccine: updates to restrictions of use following safety review

IXCHIQ Chikungunya vaccine is no longer indicated for adults over 60 years following safety review and CHM recommendations.

High impact Pharmaceuticals Public Health UK pharmacovigilancevaccination

Following the completion of a safety review and the recommendations of the Commission on Human Medicines (CHM), the IXCHIQ Chikungunya vaccine is no longer indicated for adults over the age of 60 years, and is contraindicate…

Read the official source ↗

Published by UK MHRA. HealthSignal links to the original document; the summary above is extracted from the source text.